Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

680
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
680
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

574
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
574
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

332
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

Human vaccines & immunotherapeutics·2026
Same author

Interpreting Nonsevere Tuberculosis Criteria in Children From Low-incidence Settings.

The Pediatric infectious disease journal·2026
Same author

Screening for imported infections in pediatric patients prior to immunosuppressive therapy.

Travel medicine and infectious disease·2026
Same author

Diagnostic Performance of Comprehensive Point-of-Care Ultrasound for Pediatric Tuberculosis in Spain: A Prospective Observational Study.

Journal of clinical ultrasound : JCU·2026
Same author

Contextual dimensions of pediatric tuberculosis imaging: radiation exposure, access, and system capacity in high- and low-resource settings.

Pediatric radiology·2026
Same author

Using dried blood spots to estimate Toxoplasma gondii seroprevalence in pregnant women in Catalonia, Spain, and to serologically diagnose congenital toxoplasmosis.

PLoS neglected tropical diseases·2026

Related Experiment Video

Updated: Feb 26, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K

[Tuberculosis treatment for children: An update].

María José Mellado Peña1, Begoña Santiago García2, Fernando Baquero-Artigao2

  • 1Red Española de Estudio de la Tuberculosis Pediátrica (pTBred), España; Sociedad Española de Infectología Pediátrica (SEIP), España; Red Española de Investigación Traslacional en Infectología Pediátrica (RITIP), España; European Network of Excellence for Paediatric Clinical Research (TEDDY), España.

Anales De Pediatria
|July 22, 2017
PubMed
Summary

Pediatric tuberculosis remains a significant public health issue, particularly drug-resistant strains. New guidelines offer updated recommendations for managing childhood tuberculosis, focusing on contacts and treatment.

Keywords:
DiseaseEnfermedadExposiciónExposureInfección latenteLatent infectionResistanceResistenciaTratamiento tuberculosisTuberculosis therapy

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Related Experiment Videos

Last Updated: Feb 26, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Pediatrics

Background:

  • Tuberculosis (TB) is a leading global infectious disease with high morbidity and mortality.
  • Pediatric TB is a neglected epidemic, complicated by diagnostic challenges and lower infectivity in children.
  • Multidrug-resistant TB (MDR TB) is a growing concern in Europe, with Spain having a high incidence of pediatric cases.

Purpose of the Study:

  • To address the challenges in pediatric TB management, especially drug-resistant cases.
  • To provide updated national recommendations for the care of pediatric TB patients and contacts.
  • To replace previous national guidelines with evidence-based strategies.

Main Methods:

  • Review of international guidelines and recent scientific evidence.
  • Consensus development by a national group of pediatric TB experts.
  • Formulation of new recommendations for managing pediatric TB contacts, latent infection, and active disease.

Main Results:

  • Paediatric TB is a public health priority in Spain, with over 4% prevalence of drug-resistant TB.
  • Difficulties in diagnosis and lack of pediatric drug formulations are major control challenges.
  • New recommendations cover management of contacts, latent infection, and active TB, with a focus on drug resistance.

Conclusions:

  • Updated guidelines are crucial for managing pediatric TB, especially drug-resistant forms.
  • Addressing diagnostic and therapeutic challenges is essential for controlling childhood TB.
  • These recommendations aim to improve patient outcomes and public health in Spain.